A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.
Opinion | Victory Over Big Pharma Will Take More Than the IRA
Qureshi is a second year medical student. Ramachandran is a family physician and health services researcher. During his recent State of the Union address, President